26
total announcements
MARKSANS.NS · 15 min delayed
Marksans Pharma Limited
Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026. The meeting was held through video conferencing and the results of the voting conducted through remote e-voting and e-voting during the AGM are disclosed.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding Proceedings of 34th Annual General Meeting held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the exchange about the ESG score assigned by Crisil ESG Ratings & Analytics Ltd, which is 56 for Fiscal 2026.
Marksans Pharma Limited
Marksans Pharma Limited has announced its Q1 FY27 financial results, with revenue of INR841 crores, up 35.6% year-on-year, and highest-ever quarterly EBITDA of INR213 crores and PAT of INR159 crores. The company has also completed acquisitions in Europe and established a presence in Canada and Ireland.
Marksans Pharma Limited
Marksans Pharma Limited has uploaded the audio recording of its Q1 FY 27 Financial Results investor conference call on its website.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma reported Q1FY27 financial results with record profitability, with EBITDA rising 113% YoY to ₹213 crore and PAT growing 174% YoY to ₹159 crore. The company also achieved its highest-ever quarterly revenue of ₹841 crore and crossed ₹1,000 crore in cash balance for the first time.
Marksans Pharma Limited
Marksans Pharma Limited has released its Q1FY27 investor presentation, highlighting a strong start to the year with all-time high quarterly EBITDA of ₹213 crore and PAT of ₹159 crore.
Marksans Pharma Limited
Marksans Pharma Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which have been approved by the Board of Directors. The results are available on the company's website.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding Notice of 34th AGM, record date and e-voting information published in Business Standard and Lakshadeep newspapers.
Marksans Pharma Limited
Marksans Pharma Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26, as per the provisions of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has scheduled a conference call on August 13, 2026, to discuss its unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication for AGM Intimation, regarding 34th Annual General Meeting scheduled to be held on August 27, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about the acquisition of 100 percent share capital of ABCnow GmbH, a German company.
Marksans Pharma Limited
Marksans Pharma Limited has initiated a Second 100 Day campaign 'Saksham Niveshak' to help shareholders update their KYC details, claim unclaimed dividends, and prevent transfer to IEPF.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a German-based pharmaceutical company. The acquisition will enable Marksans to use ABCnow's front-end sales and marketing infrastructure for marketing its products in the European Union.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about General Updates regarding Record Date 20 August 2026 for payment of dividend.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange about General Updates regarding Annual General Meeting scheduled to be held on 27 August 2026. The company has fixed Thursday, 20 August 2026 as the Record Date for determining eligibility of Members to receive final dividend for the financial year ended 31 March 2026.